Global Health Tests Ltd 11768987 false 2024-02-01 2025-01-31 2025-01-31 The principal activity of the company is Technical testing and analysis Digita Accounts Production Advanced 6.30.9574.0 true 11768987 2024-02-01 2025-01-31 11768987 2025-01-31 11768987 core:CurrentFinancialInstruments 2025-01-31 11768987 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 11768987 core:Non-currentFinancialInstruments core:AfterOneYear 2025-01-31 11768987 core:FurnitureFittingsToolsEquipment 2025-01-31 11768987 core:OtherPropertyPlantEquipment 2025-01-31 11768987 bus:SmallEntities 2024-02-01 2025-01-31 11768987 bus:AuditExemptWithAccountantsReport 2024-02-01 2025-01-31 11768987 bus:AbridgedAccounts 2024-02-01 2025-01-31 11768987 bus:SmallCompaniesRegimeForAccounts 2024-02-01 2025-01-31 11768987 bus:RegisteredOffice 2024-02-01 2025-01-31 11768987 bus:CompanySecretaryDirector1 2024-02-01 2025-01-31 11768987 bus:Director1 2024-02-01 2025-01-31 11768987 bus:Director5 2024-02-01 2025-01-31 11768987 bus:PrivateLimitedCompanyLtd 2024-02-01 2025-01-31 11768987 bus:Agent1 2024-02-01 2025-01-31 11768987 core:IntangibleAssetsOtherThanGoodwill 2024-02-01 2025-01-31 11768987 core:FurnitureFittingsToolsEquipment 2024-02-01 2025-01-31 11768987 core:OfficeEquipment 2024-02-01 2025-01-31 11768987 core:OtherPropertyPlantEquipment 2024-02-01 2025-01-31 11768987 core:PlantMachinery 2024-02-01 2025-01-31 11768987 countries:EnglandWales 2024-02-01 2025-01-31 11768987 2024-01-31 11768987 core:FurnitureFittingsToolsEquipment 2024-01-31 11768987 core:OtherPropertyPlantEquipment 2024-01-31 11768987 2023-02-01 2024-01-31 11768987 2024-01-31 11768987 core:CurrentFinancialInstruments 2024-01-31 11768987 core:CurrentFinancialInstruments core:WithinOneYear 2024-01-31 11768987 core:Non-currentFinancialInstruments core:AfterOneYear 2024-01-31 11768987 core:FurnitureFittingsToolsEquipment 2024-01-31 11768987 core:OtherPropertyPlantEquipment 2024-01-31 iso4217:GBP xbrli:pure

Registration number: 11768987

Global Health Tests Ltd
Annual Report and Unaudited Abridged Financial Statements
for the Year Ended 31 January 2025

Global Health Tests Ltd

Contents

Company Information | 1
Abridged Balance Sheet | 2 to 3
Notes to the Unaudited Abridged Financial Statements | 4 to 10

Global Health Tests Ltd

Company Information

Directors | J A Roan D M Christie R D J Daniels Mr Marcus John Richardson

Company secretary | D M Christie Mr Marcus John Richardson

Registered office | 71-75 Shelton Street Covent Garden London WC2H 9JQ

Accountants | 10. Chartered Accountants 10 Cheyne Walk Northampton Northamptonshire NN1 5PT

Global Health Tests Ltd

(Registration number: 11768987)
Abridged Balance Sheet as at 31 January 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Intangible assets | 5 | 253,907 | 285,440
Tangible assets | 6 | 49,085 | 22,372
|  | 302,992 | 307,812
Current assets |  |  |
Stocks | 7 | 110,506 | 29,017
Debtors |  | 572,886 | 297,668
Cash at bank and in hand |  | 282,043 | 376,742
|  | 965,435 | 703,427
Prepayments and accrued income |  | 40,066 | 27,906
Creditors: Amounts falling due within one year |  | (590,585) | (360,320)
Net current assets |  | 414,916 | 371,013
Total assets less current liabilities |  | 717,908 | 678,825
Creditors: Amounts falling due after more than one year |  | (113,657) | (125,132)
Accruals and deferred income |  | (96,952) | (120,486)
Net assets |  | 507,299 | 433,207
Capital and reserves |  |  |
Called up share capital |  | 100 | 100
Retained earnings |  | 507,199 | 433,107
Shareholders' funds |  | 507,299 | 433,207

For the financial year ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and the option to not file the profit and loss account has been taken.

Global Health Tests Ltd

(Registration number: 11768987)
Abridged Balance Sheet as at 31 January 2025

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 27 October 2025 and signed on its behalf by:

......................................... D M Christie Company secretary and director

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

1 | General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
71-75 Shelton Street
Covent Garden
London
WC2H 9JQ
United Kingdom

These financial statements were authorised for issue by the Board on 27 October 2025.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

Judgements

In applying the Company's accounting policies, the directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The directors' best judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be appropriate.
Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Office equipment | 25% on cost
Plant and machinery | 25% on cost

Intangible assets

Intangible assets are capitalised when they meet the recognition criteria, in that they are separable, probable that expected future economic benefits will flow to the entity and the cost of the asset can be measured reliably.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class | Amortisation method and rate
Software development | 10 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.
Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.
Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 17 (2024 - 11).

4 | Profit before tax

Arrived at after charging/(crediting)

| 2025 £ | 2024 £
Depreciation expense | 18,124 | 13,772
Amortisation expense | 31,532 | 31,605

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

5 | Intangible assets

| Total £
Cost or valuation
At 1 February 2024 | 382,837
At 31 January 2025 | 382,837
Amortisation
At 1 February 2024 | 97,397
Amortisation charge | 31,533
At 31 January 2025 | 128,930
Carrying amount
At 31 January 2025 | 253,907
At 31 January 2024 | 285,440

6 | Tangible assets

| Furniture, fittings and equipment £ | Other tangible assets £ | Total £
Cost or valuation
At 1 February 2024 | 38,553 | 94,506 | 133,059
Additions | 1,296 | 43,541 | 44,837
At 31 January 2025 | 39,849 | 138,047 | 177,896
Depreciation
At 1 February 2024 | 25,016 | 85,671 | 110,687
Charge for the year | 8,472 | 9,652 | 18,124
At 31 January 2025 | 33,488 | 95,323 | 128,811
Carrying amount
At 31 January 2025 | 6,361 | 42,724 | 49,085
At 31 January 2024 | 13,537 | 8,835 | 22,372

Global Health Tests Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 January 2025

7 | Stocks

| 2025 £ | 2024 £
Other inventories | 110,506 | 29,017